Reducing chronic health risks from indoor air pollution (mostly PM 2.5) generally entails different strategies than reducing infection risk from aerosols. Filtration can address both, but the airflow rates and costs can be quite different. UVC won’t do anything about PM 2.5, and may contribute to it with ozone formation.
I recommend reading the supporting literature and history behind ASHRAE Std 62.1 and Std 241, which cover ventilation and control for infectious diseases in buildings. There are also several recent studies by the National Academies on air pollution and infectious aerosols. The indoor air and infectious disease communities are quite large—with their own funding sources and conferences. It seems a lot of the “gaps” presented here are not unknown to experts, but just to the EA community and amateur researchers.
Reducing chronic health risks from indoor air pollution (mostly PM 2.5) generally entails different strategies than reducing infection risk from aerosols. Filtration can address both, but the airflow rates and costs can be quite different. UVC won’t do anything about PM 2.5, and may contribute to it with ozone formation.
I recommend reading the supporting literature and history behind ASHRAE Std 62.1 and Std 241, which cover ventilation and control for infectious diseases in buildings. There are also several recent studies by the National Academies on air pollution and infectious aerosols. The indoor air and infectious disease communities are quite large—with their own funding sources and conferences. It seems a lot of the “gaps” presented here are not unknown to experts, but just to the EA community and amateur researchers.